Edwards Lifesciences (NYSE:EW) Given New $105.00 Price Target at Mizuho

Edwards Lifesciences (NYSE:EW) had its price target upped by Mizuho from $100.00 to $105.00 in a research report released on Wednesday,Benzinga reports. Mizuho currently has an outperform rating on the medical research company’s stock.

EW has been the subject of a number of other research reports. TD Cowen restated a “buy” rating and set a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, June 2nd. Canaccord Genuity Group set a $85.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Royal Bank Of Canada lifted their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Monday. Finally, Wolfe Research upgraded shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target on the stock in a research report on Wednesday, April 1st. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus target price of $98.73.

Edwards Lifesciences Trading Down 3.2%

Shares of EW stock opened at $87.22 on Wednesday. The firm has a market cap of $50.22 billion, a P/E ratio of 46.39, a price-to-earnings-growth ratio of 2.26 and a beta of 0.86. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 12-month low of $72.30 and a 12-month high of $96.29. The business has a 50-day moving average price of $87.12 and a two-hundred day moving average price of $83.92.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The company had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm’s revenue was up 16.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities analysts anticipate that Edwards Lifesciences will post 3 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 619 shares of the stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $91.70, for a total value of $56,762.30. Following the sale, the vice president directly owned 40,034 shares in the company, valued at approximately $3,671,117.80. This represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the sale, the vice president owned 98,611 shares of the company’s stock, valued at $8,521,962.62. The trade was a 19.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 45,577 shares of company stock worth $3,855,527. Company insiders own 0.31% of the company’s stock.

Institutional Trading of Edwards Lifesciences

A number of hedge funds have recently added to or reduced their stakes in the business. Evermay Wealth Management LLC raised its stake in shares of Edwards Lifesciences by 4.0% in the 4th quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company’s stock valued at $282,000 after acquiring an additional 128 shares during the period. Rehmann Capital Advisory Group grew its stake in Edwards Lifesciences by 2.1% during the 4th quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock worth $546,000 after purchasing an additional 130 shares in the last quarter. Florida Trust Wealth Management Co increased its stake in shares of Edwards Lifesciences by 1.5% during the fourth quarter. Florida Trust Wealth Management Co now owns 8,810 shares of the medical research company’s stock worth $751,000 after buying an additional 132 shares during the period. McIlrath & Eck LLC raised its holdings in shares of Edwards Lifesciences by 14.6% in the 4th quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company’s stock valued at $90,000 after purchasing an additional 135 shares in the last quarter. Finally, Quadrant Capital Group LLC raised its stake in Edwards Lifesciences by 0.9% in the fourth quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company’s stock valued at $1,288,000 after buying an additional 136 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.